Input Symbol
(pharmaceutics and related company):

Show Other Options

US Clinical Trail Options
Field(s): Type(s): Status(es): Phase(s):
Default Sorting:
US FDA Submission Options
Field(s): Class(s): Type(s):
US Drug Marketing Status Options
Field(s):
EU Drug Marketing Status Options
Field(s):
CA Drug Marketing Status Options
Field(s):
General Options
Historical Years: Display Records Number:
Plot Options & Overlay
Price Chart: Technical Indicators: Clinical Trails: FDA Submissions:
US Marketing: EU Marketing: CA Marketing:
Full Name:Teva Pharmaceutical Industries Limited Industry:pharmaceuticals CIK:818686 Fiscal Year End:12-31 State/Country:ISRAEL

Check Quant Chart for other overlays (E.g. SEC filings, Insider tradings) to get more accurate projection of price movement

Show Plot Instructions       Expand All

Instructions

US clinical trial status

Size of symbol reflects the phase of clinical trial. E.g. Phase 3 trial has the largest size.
Shape definition
Up-triangle: study first submitted.
Square: study completion(actual/anticipated).
Circle: result first posted.
Color definition
Green: study is ongoing.
Blue: recruitment completed.
Red: study aborted/terminated/withdrawn.
Pink: study in abnormal state.

US FDA submission

Size of symbol reflects the type of submission. E.g. Type 1 drug has the largest size.
: Approved.
: Tentative Approval.

Drug marketing & current status

Circle bubble denotes new drug marketing. Size is determined by drug type and market(i.e. population) size. E.g. Type 1 drug marketed in US has the largest size. Drug marketed in CA has the smallest size due to small population size.
Color definition
Blue circle: drug marketed (EU,CA), FDA submission approved (US).
Cyan circle: drug approved (CA), tentative approval (US), received positive opinion (EU)
Red circle: drug marketed/approved on the corresponding day but was later withdrawn, discontinued, cancelled, or received negative opinion.

Drug marketing status change

Square bubble denotes marketing status change. Size is determined by drug type and market(i.e. population) size.
Color definition
Blue square: change from other status to marketed.
Cyan square: change from other status to tentative status.
Red square: change from other status to abnormal or withdrawn status.

US Clinical Trials

Clinical Trials Summary Statistics

Year Recruiting Active, Not Recruiting Completed Unknown Status Terminated Withdrawn
ALL 4 193 4
2024 4
2023
2022
Year Recruiting Active, Not Recruiting Completed Unknown Status Terminated Withdrawn
ALL 8 4
2024
2023
2022
Year Recruiting Active, Not Recruiting Completed Unknown Status Terminated Withdrawn
ALL 2 41 8 6
2024
2023
2022 2
Year Recruiting Active, Not Recruiting Completed Unknown Status Terminated Withdrawn
ALL 3
2024
2023
2022
Year Recruiting Active, Not Recruiting Completed Unknown Status Terminated Withdrawn
ALL 3 2 82 1 15 1
2024
2023 1 1
2022 1 2
Year Recruiting Active, Not Recruiting Completed Unknown Status Terminated Withdrawn
ALL 15 5 1
2024
2023
2022
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3 Phase 4
ALL 4 2 3
2024 4
2023 1
2022 2
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3 Phase 4
ALL 2
2024
2023 1
2022 1
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3 Phase 4
ALL 193 8 41 3 82 15
2024
2023
2022 2
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3 Phase 4
ALL 1
2024
2023
2022
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3 Phase 4
ALL 4 4 8 15 5
2024
2023
2022
Year Phase 1 Phase 1|Phase 2 Phase 2 Phase 2|Phase 3 Phase 3 Phase 4
ALL 6 1 1
2024
2023
2022
Phase Recruiting Active, Not Recruiting Completed Unknown Status Terminated Withdrawn
Phase 1 4 193 4
Phase 1|Phase 2 8 4
Phase 2 2 41 8 6
Phase 2|Phase 3 3
Phase 3 3 2 82 1 15 1
Phase 4 15 5 1
Phase Recruiting Active, Not Recruiting Completed Unknown Status Terminated Withdrawn
Phase 1 4
Phase 1|Phase 2
Phase 2
Phase 2|Phase 3
Phase 3
Phase 4
Phase Recruiting Active, Not Recruiting Completed Unknown Status Terminated Withdrawn
Phase 1
Phase 1|Phase 2
Phase 2
Phase 2|Phase 3
Phase 3 1 1
Phase 4
Phase Recruiting Active, Not Recruiting Completed Unknown Status Terminated Withdrawn
Phase 1
Phase 1|Phase 2
Phase 2 2
Phase 2|Phase 3
Phase 3 1 2
Phase 4

Note: "Year" represents clinical trail start year determined by study first submit date.
Three grouping strategies present the same statistical data from different angles, choose any one you are comfortable with.
at least one study with latest update posted within 7 days.  at least one study with latest update posted within 30 days.  at least one study with latest update posted within 90 days. 

Clinical Trials Records

Sponsor Overall Status Phase Brief Title Disease Condition Intervention Name Study First Submit Date Last Update Post Date Results First Post Date Completion Date Completion Date Type Enrollment Count
Teva Branded Pharmaceutical Products R&D, Inc. Recruiting Phase 3 A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations Asthma TEV-56248|Albuterol sulfate 2023-09-18 2024-04-17 2026-07-17 Anticipated 2196
Teva Branded Pharmaceutical Products R&D, Inc. Active, not recruiting Phase 3 A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia Schizophrenia TV-44749 - Dose level 1|TV-44749 - Dose level 2|TV-44749 - Dose level 3|Placebo 2023-01-12 2024-04-22 2025-01-13 Anticipated 675
Teva Pharmaceuticals USA Completed Phase 3 Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy Dyspareunia Estradiol|Imvexxy|Placebo 2022-11-07 2024-04-12 2024-03-15 Actual 1050
Teva Pharmaceuticals USA Completed Phase 3 Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris Acne Vulgaris Trifarotene 0.005 % Topical Cream|AKLIEF®|Placebo 2022-09-19 2023-08-24 2023-05-09 Actual 807
Teva Branded Pharmaceutical Products R&D, Inc. Active, not recruiting Phase 3 A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine Migraine Fremanezumab|Placebo 2022-07-11 2024-02-08 2024-07-03 Anticipated 365

Note: Use 'Search' box on top right cornor to narrow down search results. E.g. type in "phase 3" (case insensitive, with double quote) to show Phase 3 trials.
latest update posted within 7 days.  latest update posted within 30 days.  latest update posted within 90 days. 

US FDA Submissions

US FDA Submission Summary Statistics*

Year TYPE 1 TYPE 2 TYPE 2/4 TYPE 3 TYPE 4 TYPE 5 TYPE 9 N/A UNKNOWN
ALL 17 3 1 29 3 16 1 14 148
2024
2023 2 12
2022 1 1 30

Note: "Year" determined by submission status date.
* Original submissions only. Supplementary records not counted.
at least one submission within 7 days.  at least one submission within 30 days.  at least one submission within 90 days. 

US FDA Submission Records

Sponsor Application Type Drug Name Active Ingredient Submission Code Submission Type Submission Status Status Date Application Number
Teva Pharms Inc ANDA Orig 1 Tentative 2024-03-08 216931
Teva Pharms Usa Inc ANDA Orig 1 Tentative 2024-02-01 209813
Teva Pharms Usa Inc ANDA Cyclosporine Cyclosporine Orig 1 Approval 2023-12-14 203880
Teva Pharms Usa Inc ANDA Octreotide Acetate Octreotide Acetate Orig 1 Approval 2023-12-05 210317
Teva Pharms Usa Inc ANDA Risperidone Risperidone Orig 1 Approval 2023-12-05 214068
Teva Pharms Usa ANDA Teriparatide Teriparatide Orig 1 Approval 2023-11-16 208569
Teva Pharms Inc ANDA Unknown Orig Tentative Approval 2023-10-26 217825
Teva Pharms Inc ANDA Pazopanib Pazopanib Unknown Orig Approval 2023-10-19 217517
Teva Pharms Usa Inc ANDA Unknown Orig Tentative Approval 2023-08-29 217635
Teva Pharms ANDA Lisdexamfetamine Dimesylate Lisdexamfetamine Dimesylate Unknown Orig Approval 2023-08-25 215415
Teva Pharms Usa Inc ANDA Plerixafor Plerixafor Unknown Orig Approval 2023-07-24 205197
Teva Pharms Usa Inc ANDA Naltrexone Naltrexone Unknown Orig Approval 2023-07-06 213195
Teva Pharms Inc ANDA Unknown Orig Tentative Approval 2023-05-23 216770
Teva Pharms Inc NDA Paclitaxel Paclitaxel Type 5 Orig Approval 2023-05-11 216338
Teva NDA Uzedy Risperidone Type 5 Orig Approval 2023-04-28 213586
Teva Pharms ANDA Doxepin Hydrochloride Doxepin Hydrochloride Unknown Orig Approval 2023-02-17 215408
Teva NDA Austedo Xr Deutetrabenazine Unknown Orig Approval 2023-02-17 216354
Teva Pharms Usa ANDA Methylphenidate Hydrochloride Methylphenidate Hydrochloride Unknown Orig Tentative Approval 2023-02-07 214202
Teva Pharms Usa ANDA Abiraterone Acetate Abiraterone Acetate Unknown Orig Approval 2023-01-26 210726
Teva Pharms Usa Inc ANDA Aspirin; Omeprazole Aspirin;Omeprazole Unknown Orig Tentative Approval 2023-01-20 209791
Teva Pharms Usa Inc ANDA Tasimelteon Tasimelteon Unknown Orig Approval 2022-12-12 211601
Teva Pharms Inc ANDA Valbenazine Tosylate Valbenazine Tosylate Unknown Orig Tentative Approval 2022-11-25 215984
Teva Pharms Usa ANDA Penciclovir Penciclovir Unknown Orig Approval 2022-11-09 212710
Teva Pharms Usa Inc ANDA Oxymetazoline Oxymetazoline Unknown Orig Tentative Approval 2022-10-28 211812
Teva Pharms Inc ANDA Cabozantinib Cabozantinib Unknown Orig Tentative Approval 2022-10-27 215942
Teva Pharms Inc ANDA Alyq Tadalafil Unknown Orig Approval 2022-10-12 216932
Teva Pharms Inc ANDA Theophylline Theophylline Unknown Orig Approval 2022-10-12 216961
Watson Labs Teva ANDA Brimonidine Tartrate And Timolol Maleate Brimonidine Tartrate; Timolol Maleate N/A Orig Approval 2022-10-04 201949
Teva Pharms NDA Alvaiz Eltrombopag Choline Type 2 Orig Tentative Approval 2022-10-03 216774
Teva Pharms Usa ANDA Deferasirox Deferasirox Unknown Orig Approval 2022-09-23 207124
Teva Pharms Usa Inc ANDA Apremilast Apremilast Unknown Orig Approval 2022-08-18 211897
Teva Pharms Inc ANDA Cetrorelix Acetate Cetrorelix Acetate Unknown Orig Approval 2022-08-12 215737
Teva Pharms Usa Inc ANDA Brexpiprazole Brexpiprazole Unknown Orig Approval 2022-08-11 213692
Teva Pharms Usa Inc ANDA Dapagliflozin;Metformin Hydrochloride Dapagliflozin;Metformin Hydrochloride Unknown Orig Tentative Approval 2022-08-03 211583
Teva Pharms Usa Inc ANDA Perampanel Perampanel Unknown Orig Tentative Approval 2022-07-01 209801
Teva Pharms Usa Inc ANDA Dasatinib Dasatinib Unknown Orig Tentative Approval 2022-07-01 211094
Teva Pharms Usa ANDA Abiraterone Acetate Abiraterone Acetate Unknown Orig Approval 2022-06-24 212206
Teva Pharms Usa ANDA Canagliflozin Canagliflozin Unknown Orig Tentative Approval 2022-06-14 210451
Watson Labs Teva ANDA Levothyroxine Sodium Levothyroxine Sodium Unknown Orig Approval 2022-05-10 207588
Teva Pharms Usa ANDA Mesalamine Mesalamine Unknown Orig Approval 2022-05-06 209970
Teva Pharms Usa ANDA Pomalidomide Pomalidomide Unknown Orig Approval 2022-05-04 209956
Teva Pharms Usa ANDA Zileuton Zileuton Unknown Orig Approval 2022-05-03 211043
Teva Pharms Usa ANDA Bortezomib Bortezomib Unknown Orig Approval 2022-05-02 205857
Teva Pharms Usa ANDA Dofetilide Dofetilide Unknown Orig Approval 2022-04-15 210018
Teva Pharms Usa Inc ANDA Riociguat Riociguat Unknown Orig Tentative Approval 2022-03-30 211044
Teva Pharms Usa ANDA Ivermectin Ivermectin Unknown Orig Approval 2022-03-21 212485
Teva Pharms ANDA Unknown Orig Tentative Approval 2022-02-23 216076
Teva Pharms Usa ANDA Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Unknown Orig Approval 2022-01-31 210876
Teva Pharms Usa Inc ANDA Sofosbuvir Sofosbuvir Unknown Orig Approval 2022-01-27 211353
Teva Pharms Usa ANDA Pirfenidone Pirfenidone Unknown Orig Approval 2022-01-25 212759
Teva Pharms Usa ANDA Mycophenolate Mofetil Mycophenolate Mofetil Unknown Orig Approval 2022-01-25 211272

Note: Use 'Search' box on top right cornor to narrow down search results. E.g. type in "NDA" (case insensitive) to show records with "NDA" (New Drug Applications) tag.
submission status date within 7 days.  submission status date within 30 days.  submission status date within 90 days. 

US Drug Marketing Status
Category Sponsor Marketing Date Current Marketing Status Drug Name Active Ingredient Submission Status Date Submission Code Submission Status Marketing Status Change Date
Human Non-Bioproduct Teva Pharms Inc None (Tentative Approval) 2023-10-26 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Inc None (Tentative Approval) 2023-10-26 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Inc None (Tentative Approval) 2023-10-26 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Inc None (Tentative Approval) 2023-10-26 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Inc 2023-10-19 Prescription Pazopanib Pazopanib 2023-10-19 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Usa Inc None (Tentative Approval) 2023-08-29 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms 2023-08-25 Prescription Lisdexamfetamine Dimesylate Lisdexamfetamine Dimesylate 2023-08-25 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva Pharms 2023-08-25 Prescription Lisdexamfetamine Dimesylate Lisdexamfetamine Dimesylate 2023-08-25 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva Pharms 2023-08-25 Prescription Lisdexamfetamine Dimesylate Lisdexamfetamine Dimesylate 2023-08-25 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva Pharms 2023-08-25 Prescription Lisdexamfetamine Dimesylate Lisdexamfetamine Dimesylate 2023-08-25 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva Pharms 2023-08-25 Prescription Lisdexamfetamine Dimesylate Lisdexamfetamine Dimesylate 2023-08-25 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva Pharms 2023-08-25 Prescription Lisdexamfetamine Dimesylate Lisdexamfetamine Dimesylate 2023-08-25 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Usa Inc 2023-07-24 Prescription Plerixafor Plerixafor 2023-07-24 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Usa Inc 2023-07-06 Prescription Naltrexone Naltrexone 2023-07-06 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Inc None (Tentative Approval) 2023-05-23 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Inc None (Tentative Approval) 2023-05-23 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Inc 2023-05-11 Prescription Paclitaxel Paclitaxel 2023-05-11 Type 5 Approval 2023-11-30
Human Non-Bioproduct Teva 2023-04-28 Prescription Uzedy Risperidone 2023-04-28 Type 5 Approval 2023-11-30
Human Non-Bioproduct Teva 2023-04-28 Prescription Uzedy Risperidone 2023-04-28 Type 5 Approval 2023-11-30
Human Non-Bioproduct Teva 2023-04-28 Prescription Uzedy Risperidone 2023-04-28 Type 5 Approval 2023-11-30
Human Non-Bioproduct Teva 2023-04-28 Prescription Uzedy Risperidone 2023-04-28 Type 5 Approval 2023-11-30
Human Non-Bioproduct Teva 2023-04-28 Prescription Uzedy Risperidone 2023-04-28 Type 5 Approval 2023-11-30
Human Non-Bioproduct Teva 2023-04-28 Prescription Uzedy Risperidone 2023-04-28 Type 5 Approval 2023-11-30
Human Non-Bioproduct Teva 2023-04-28 Prescription Uzedy Risperidone 2023-04-28 Type 5 Approval 2023-11-30
Human Non-Bioproduct Teva 2023-02-17 Prescription Austedo Xr Deutetrabenazine 2023-02-17 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva 2023-02-17 Prescription Austedo Xr Deutetrabenazine 2023-02-17 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva 2023-02-17 Prescription Austedo Xr Deutetrabenazine 2023-02-17 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva Pharms 2023-02-17 Prescription Doxepin Hydrochloride Doxepin Hydrochloride 2023-02-17 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Usa None (Tentative Approval) Methylphenidate Hydrochloride Methylphenidate Hydrochloride 2023-02-07 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Usa None (Tentative Approval) Methylphenidate Hydrochloride Methylphenidate Hydrochloride 2023-02-07 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Usa None (Tentative Approval) Methylphenidate Hydrochloride Methylphenidate Hydrochloride 2023-02-07 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Usa 2023-01-26 Prescription Abiraterone Acetate Abiraterone Acetate 2023-01-26 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Usa Inc None (Tentative Approval) Aspirin; Omeprazole Aspirin;Omeprazole 2023-01-20 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Usa Inc None (Tentative Approval) Aspirin; Omeprazole Aspirin;Omeprazole 2023-01-20 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Usa Inc 2022-12-12 Prescription Tasimelteon Tasimelteon 2022-12-12 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Inc None (Tentative Approval) Valbenazine Tosylate Valbenazine Tosylate 2022-11-25 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Inc None (Tentative Approval) Valbenazine Tosylate Valbenazine Tosylate 2022-11-25 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Usa 2022-11-09 Prescription Penciclovir Penciclovir 2022-11-09 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Usa Inc None (Tentative Approval) Oxymetazoline Oxymetazoline 2022-10-28 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Inc Prescription Cabozantinib Cabozantinib 2022-10-27 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Inc Prescription Cabozantinib Cabozantinib 2022-10-27 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Inc Prescription Cabozantinib Cabozantinib 2022-10-27 Unknown Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Inc 2022-10-12 Prescription Theophylline Theophylline 2022-10-12 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Inc 2022-10-12 Prescription Theophylline Theophylline 2022-10-12 Unknown Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Inc 2022-10-12 Prescription Alyq Tadalafil 2022-10-12 Unknown Approval 2023-11-30
Human Non-Bioproduct Watson Labs Teva 2022-10-04 Prescription Brimonidine Tartrate And Timolol Maleate Brimonidine Tartrate; Timolol Maleate 2022-10-04 N/A Approval 2023-11-30
Human Non-Bioproduct Teva Pharms None (Tentative Approval) Alvaiz Eltrombopag Choline 2022-10-03 Type 2 Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms None (Tentative Approval) Alvaiz Eltrombopag Choline 2022-10-03 Type 2 Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms None (Tentative Approval) Alvaiz Eltrombopag Choline 2022-10-03 Type 2 Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms None (Tentative Approval) Alvaiz Eltrombopag Choline 2022-10-03 Type 2 Tentative Approval 2023-11-30
Human Non-Bioproduct Teva Pharms Usa 2022-09-23 Discontinued Deferasirox Deferasirox 2022-09-23 Unknown Approval 2023-11-30

Note: This table contains human and animal drugs regulated by US FDA, and biological products regulated by CBER (Center for Biologics Evaluation and Research).
Use 'Search' box on top right cornor to narrow down search results. E.g. type in "discontinued" (case insensitive) to show discontinued drug products.
For human non-bioproduct, marketing date was set to submission approval date.
Possible marketing statuses: Marketed, Prescription, Over-the-counter, Discontinued, None (Tentative Approval).
any of (marketing/submission/status change) within 7 days.  any of (marketing/submission/status change) within 30 days.  any of (marketing/submission/status change) within 90 days. 

EU Drug Marketing Status
Category Sponsor Authorization Date Current Marketing Status Latest Status Update Drug Name Active Ingredient Withdraw Date Opinion Date Summary of Opinion
Human Teva Gmb H 2022-12-12 Authorised 2022-12-22 Dimethyl fumarate Teva Dimethyl Fumarate
Human Teva B.V. 2012-03-26 Withdrawn 2023-05-04 Pioglitazone Teva Pioglitazone Hydrochloride
Human Teva Pharma B.V. 2012-03-26 Withdrawn 2022-08-30 Pioglitazone Teva Pharma Pioglitazone Hydrochloride
Human Teva Pharma B.V. 2011-02-28 Withdrawn 2023-03-21 Lamivudine/Zidovudine Teva Lamivudine, Zidovudine
Human Teva B.V. 2009-11-30 Withdrawn 2023-03-21 Nevirapine Teva Nevirapine

Note: This table contains human and animal drugs regulated by EMA (European Medicines Agency), and summary of opinion published by EMA based on the CHMP's or CVMP's positive or negative recommendation.
Use 'Search' box on top right cornor to narrow down search results. E.g. type in "withdrawn" (case insensitive) to show drugs withdrawn.
Possible marketing statuses: Authorised, Refused, Withdrawn, Summary of Opinion.
Summary of Opinion: published by European Medicines Agency (EMA) based on the CHMP's or CVMP's positive or negative recommendation. Further marketing authorization is partially based on this opinion.
any of (authorization/withdrawn/opinion/status change) date within 7 days.  any of (authorization/withdrawn/opinion/status change) date within 30 days.  any of (authorization/withdrawn/opinion/status change) date within 90 days. 

CA Drug Marketing Status
Category Sponsor Authorization Date Current Marketing Status Status Date Drug Name Active Ingredient
Human Teva Canada Limited 2009-07-09 Dormant 2024-03-19 Act Amlodipine Amlodipine (Amlodipine Besylate) (2.5 Mg)
Human Teva Canada Limited 2001-09-10 Dormant 2024-02-28 Teva Levocarbidopa Carbidopa (10 Mg)|Levodopa (100 Mg)
Human Teva Canada Limited 2023-10-11 Marketed 2024-02-26 Ranopto Ranibizumab (10 Mg)
Human Teva Canada Limited 2002-11-05 Cancelled Pre Market 2024-02-20 Fluvoxamine Tablets Fluvoxamine Maleate (100 Mg)
Human Teva Canada Limited 2002-11-05 Cancelled Pre Market 2024-02-20 Fluvoxamine Tablets Fluvoxamine Maleate (50 Mg)
Human Teva Canada Limited 2024-02-19 Approved 2024-02-19 Atorvastatin Atorvastatin (Atorvastatin Calcium) (10 Mg)
Human Teva Canada Limited 2024-02-19 Approved 2024-02-19 Atorvastatin Atorvastatin (Atorvastatin Calcium) (20 Mg)
Human Teva Canada Limited 2024-02-19 Approved 2024-02-19 Atorvastatin Atorvastatin (Atorvastatin Calcium) (40 Mg)
Human Teva Canada Limited 2024-02-19 Approved 2024-02-19 Atorvastatin Atorvastatin (Atorvastatin Calcium) (80 Mg)
Human Teva Canada Limited 2004-07-05 Marketed 2024-02-16 Teva Fluvoxamine Fluvoxamine Maleate (50 Mg)
Human Teva Canada Limited 2004-07-05 Marketed 2024-02-16 Teva Fluvoxamine Fluvoxamine Maleate (100 Mg)
Human Teva Canada Limited 2003-12-09 Marketed 2024-02-15 Teva Paroxetine Paroxetine (Paroxetine Hydrochloride Acetone Solvate) (20 Mg)
Human Teva Canada Limited 2003-12-09 Marketed 2024-02-15 Teva Paroxetine Paroxetine (Paroxetine Hydrochloride Acetone Solvate) (30 Mg)
Human Teva Canada Limited 2003-12-09 Marketed 2024-02-15 Teva Paroxetine Paroxetine (Paroxetine Hydrochloride Acetone Solvate) (10 Mg)
Human Teva Canada Limited 2024-01-02 Marketed 2024-01-08 Teva Naloxone Nasal Spray Naloxone Hydrochloride (4 Mg)
Human Teva Canada Limited 2024-01-03 Approved 2024-01-03 Teva Tofacitinib Tofacitinib (Tofacitinib Citrate) (5 Mg)
Human Teva Canada Limited 2024-01-03 Approved 2024-01-03 Teva Tofacitinib Tofacitinib (Tofacitinib Citrate) (10 Mg)
Human Teva Canada Limited 2017-05-01 Marketed 2023-12-01 Teva Olmesartan / Hctz Olmesartan Medoxomil (20 Mg)|Hydrochlorothiazide (12.5 Mg)
Human Teva Canada Limited 2015-09-18 Cancelled Pre Market 2023-11-16 Qnasl Beclomethasone Dipropionate (40 Mcg)
Human Teva Canada Limited 2015-09-18 Cancelled Pre Market 2023-11-16 Qnasl Beclomethasone Dipropionate (80 Mcg)
Human Teva Canada Limited 2023-11-01 Marketed 2023-11-01 Teva Rivaroxaban Rivaroxaban (10 Mg)
Human Teva Canada Limited 2023-11-01 Marketed 2023-11-01 Teva Rivaroxaban Rivaroxaban (15 Mg)
Human Teva Canada Limited 2023-11-01 Marketed 2023-11-01 Teva Rivaroxaban Rivaroxaban (20 Mg)
Human Teva Canada Limited 2022-09-20 Marketed 2023-09-22 Teva Apixaban Apixaban (2.5 Mg)
Human Teva Canada Limited 2022-09-20 Marketed 2023-09-22 Teva Apixaban Apixaban (5 Mg)
Human Teva Canada Limited 2023-09-18 Approved 2023-09-18 Teva Mirtazapine Mirtazapine (15 Mg)
Human Teva Canada Limited 2023-09-18 Approved 2023-09-18 Teva Mirtazapine Mirtazapine (45 Mg)
Human Teva Canada Limited 2004-10-22 Marketed 2023-09-18 Teva Mirtazapine Mirtazapine (30 Mg)
Human Teva Canada Limited 2023-09-11 Marketed 2023-09-11 Teva Sunitinib Sunitinib (Sunitinib Malate) (12.5 Mg)
Human Teva Canada Limited 2023-09-11 Marketed 2023-09-11 Teva Sunitinib Sunitinib (Sunitinib Malate) (25 Mg)
Human Teva Canada Limited 2023-09-11 Marketed 2023-09-11 Teva Sunitinib Sunitinib (Sunitinib Malate) (50 Mg)
Human Teva Canada Limited 2023-01-05 Marketed 2023-08-31 Teva Sitagliptin Malate Sitagliptin (Sitagliptin Malate) (25 Mg)
Human Teva Canada Limited 2023-01-05 Marketed 2023-08-31 Teva Sitagliptin Malate Sitagliptin (Sitagliptin Malate) (50 Mg)
Human Teva Canada Limited 2023-01-05 Marketed 2023-08-31 Teva Sitagliptin Malate Sitagliptin (Sitagliptin Malate) (100 Mg)
Human Teva Canada Limited 2013-11-25 Cancelled Post Market 2023-06-28 Novo Profen Ibuprofen (300 Mg)
Human Teva Canada Limited 2004-08-24 Marketed 2023-06-15 Teva Metformin Metformin Hydrochloride (500 Mg)
Human Teva Canada Limited 2004-08-24 Marketed 2023-06-15 Teva Metformin Metformin Hydrochloride (850 Mg)
Human Teva Canada Limited 2022-09-22 Cancelled Pre Market 2023-05-24 Teva Lenalidomide Lenalidomide (Lenalidomide Hydrochloride Monohydrate) (2.5 Mg)
Human Teva Canada Limited 2022-09-22 Cancelled Pre Market 2023-05-24 Teva Lenalidomide Lenalidomide (Lenalidomide Hydrochloride Monohydrate) (5 Mg)
Human Teva Canada Limited 2022-09-22 Cancelled Pre Market 2023-05-24 Teva Lenalidomide Lenalidomide (Lenalidomide Hydrochloride Monohydrate) (10 Mg)
Human Teva Canada Limited 2022-09-22 Cancelled Pre Market 2023-05-24 Teva Lenalidomide Lenalidomide (Lenalidomide Hydrochloride Monohydrate) (15 Mg)
Human Teva Canada Limited 2022-09-22 Cancelled Pre Market 2023-05-24 Teva Lenalidomide Lenalidomide (Lenalidomide Hydrochloride Monohydrate) (20 Mg)
Human Teva Canada Limited 2022-09-22 Cancelled Pre Market 2023-05-24 Teva Lenalidomide Lenalidomide (Lenalidomide Hydrochloride Monohydrate) (25 Mg)
Human Teva Canada Limited 2023-05-15 Approved 2023-05-15 Teva Dapagliflozin Dapagliflozin (5 Mg)
Human Teva Canada Limited 2023-05-15 Approved 2023-05-15 Teva Dapagliflozin Dapagliflozin (10 Mg)
Human Teva Canada Limited 2018-08-24 Cancelled Post Market 2023-04-18 Trisenox Arsenic Trioxide (12 Mg)
Human Teva Canada Limited 2008-04-11 Marketed 2023-03-22 Teva Pantoprazole Pantoprazole (Pantoprazole Sodium Sesquihydrate) (20 Mg)
Human Teva Canada Limited 2008-04-11 Marketed 2023-03-22 Teva Pantoprazole Pantoprazole (Pantoprazole Sodium Sesquihydrate) (40 Mg)
Human Teva Canada Limited 2010-01-20 Cancelled Post Market 2023-03-21 Teva Methylphenidate Er C Methylphenidate Hydrochloride (18 Mg)
Human Teva Canada Limited 2010-01-20 Cancelled Post Market 2023-03-21 Teva Methylphenidate Er C Methylphenidate Hydrochloride (27 Mg)
Human Teva Canada Limited 2010-01-20 Cancelled Post Market 2023-03-21 Teva Methylphenidate Er C Methylphenidate Hydrochloride (36 Mg)

Note: This table contains human, animal drugs, radiopharmaceutical and disinfectant regulated by CFIA(Canadian Food Inspection Agency) and Health Canada.
Use 'Search' box on top right cornor to narrow down search results. E.g. type in "marketed" (case insensitive) to show drugs marketed.
Possible marketing statuses: Marketed, Approved, Dormant, Cancelled Pre Market, Cancelled Post Market, Cancelled (Safety Issue), Cancelled (Unreturned Annual).
any of (authorization/status change) date within 7 days.  any of (authorization/status change) date within 30 days.  any of (authorization/status change) date within 90 days.